Jay Lefton Email Address

M and A and Securities and Tech and Life Sciences and Israel and West Bank Initiative @ Fasken

Fasken Martineau is an international business law and litigation firm with 700 lawyers worldwide.

Jay practises in the area of corporate and securities law, including public and private financings, mergers, acquisitions and take-over bids, private equity, and strategic alliances, technology transfer and licensing, with an emphasis on technology and life sciences companies. He represents and advises issuers (both publicly and privately owned), special committees, advisors, venture capitalists, institutional investors, private equity funds, research institutions and researchers at various stages in the commercialization of their discoveries. Jay is the Toronto Regional Leader of the firm's Venture Capital Group, and takes the lead in the firm's Israel and West Bank initiative.Jay has advised acquirors and target companies and their Boards of Directors in connection with negotiated transactions and unsolicited take-over bids, many of which are multijurisdictional in nature.Jay has been recognized in "The International Who's Who of Lawyers" in the categories of Mergers & Acquisitions and Life Sciences (Transactions) for Canada, as well as "The Best Lawyers in Canada" in the categories of Mergers & Acquisitions, Securities Law and Biotechnology Law. He has also been recognized in PLC's "Which Lawyer?" in the category of Life Sciences for Corporate and Commercial lawyers, and in the Lexpert / American Lawyer Guide to the Leading 500 Lawyers for Canada as "most frequently recommended" for Corporate Mid-Market and “repeatedly recommended” in Private Equity and "repeatedly recommended" in Biotechnology. Jay is a former member of the Ontario Securities Commission’s Securities Advisory Committee, which provides advice to the Commission on various matters, including legislative and policy initiatives.Specialties: corporate and securities law, including public and private financings, mergers, acquisitions and take-over bids, private equity, and strategic alliances, technology transfer and licensing, with an emphasis on technology and life sciences companies